Introduction
============

The increase in the applications of manufactured nanoparticles, which are composed mostly of metal and metal oxides, is increasing the potential for exposure among manufacturers and consumers.[@b1-ijn-6-855] The major toxicological concern associated with manufactured nanomaterials is that some of are redox active, and some particles are transported across cell membranes and interact with subcellular organelles.[@b2-ijn-6-855] Thus, evaluation of their toxicity on acute and subchronic exposure is essential.

The medical use of silver dates back centuries. Many of the industrial silver compounds, including nitrate, chloride, bromide, acetate, oxide, sulfate, and cyanide,[@b3-ijn-6-855] can be released in to the environment from various sources.[@b4-ijn-6-855] Silver can be found in low levels in many tissues,[@b4-ijn-6-855]--[@b7-ijn-6-855] but without any clear physiologic function. Dermal exposure to high doses of silver causes argyria and mild allergic responses.[@b8-ijn-6-855] but the toxicity profile of dermal exposure to nanosilver with acute and subchronic treatment has not yet been identified.

Silver has been used as an antimicrobial agent for a long time in the form of metallic silver and silver sulfadiazine ointments.[@b9-ijn-6-855] However, it has recently been reported that nanosilver in the form of colloidal silver has been used for more than 100 years and has been registered as a biocidal material in the United States since 1954.[@b10-ijn-6-855] Silver nanoparticles have recently been recognized as antimicrobial agents and are finding diverse medical applications such as silver-based dressings and, silver-coated medical devices.[@b11-ijn-6-855],[@b12-ijn-6-855] This nanoparticle can damage bacterial cell walls and cause cell death.[@b13-ijn-6-855] Although nanosilver magnifies the therapeutic effects of silver, its safety profile has remained controversial compared with silver compounds. Because of the importance of dermal exposure to nanosilver in different health products we compared the dermal toxicity of nanosilver and silver nitrate (AgNO~3~) in the guinea pig by acute and subchronic tests.

Materials and methods
=====================

Silver nanoparticles
--------------------

Silver nanoparticles were purchased from QuantumSphere Inc., (Santa Ana, CA). Three different aqueous solutions (100, 1000, and 10,000 μg/mL) were provided by Dr K Gilani in the Pharmaceutics Lab., Faculty of Pharmacy, Tehran University of Medical Sciences.

Experimental animals and housing conditions
-------------------------------------------

Forty-eight experimental male Hartley albino guinea pigs were obtained from the Pasteur Institute of Iran at five to six weeks of age and 350 to 450 g body weight. All guinea pigs were housed in stainless steel cages and allowed to adapt to the conditions of the animal house for 14 days before the experiments. The animals were maintained on a 12 hour dark/light cycle at about 22 ±3°C and allowed free access to a standard laboratory diet, vitamin C, and tap water ad libitum during the experiments. The 48 animals were randomly divided to eight treatment groups of six animals each. Three groups were allocated to an acute dermal toxicity assessment and the other five to a subchronic dermal toxicity assessment. All animal studies were conducted according to the US National Institute of Health (NIH publication no. 85-23, revised 1985) guidelines.

Transmission electron microscopy and X-ray diffraction tests
------------------------------------------------------------

The extent and size of silver nanoparticles were determined by transmission electron microscopy (TEM) and X-ray diffraction (XRD) using standard equipment (Siemens with Cu source, 40 kV and 30 mA). Sample patterns were determined at 5 to 75 degrees (2*ϑ*).[@b14-ijn-6-855]

Acute dermal toxicity studies
-----------------------------

The acute dermal toxicity test was performed in compliance with the OECD guideline o402. After performing a toxicity test at up to 10,000 μg/mL on three animals, six male animals per group were used for the acute test. This preliminary study estimated the dermal LD50 of this substance and served a basis for classification and labeling of dermal nanosilver. It was the initial step for establishing the dosage regimen in the subchronic toxicity test. The Draize test was used also initially to assess primary skin irritation potential of the test material.[@b15-ijn-6-855]

The test substance at 100 and 1000 μg/mL and 100 μg/mL of a solution of AgNO~3~ were applied to 10% of the body surface area of experimental animals and positive control animals, respectively. Untreated portions of the body surface area of all animals served as negative controls. The shaved and rubbed areas were covered with sterile gas and fixed with cloth glue. Animals were put inside a restrainer for a period of four to five hours and the skin of each animal was studied in intervals of 1, 24, 48, and 72 hours for presence of any edema, erythema, or any type of dermal change.

Observations continued for 14 days. During the first day the animals were observed frequently and then observations were made daily. Necropsy of all animals was carried out and all gross pathologic changes were studied.

Subchronic dermal toxicity studies
----------------------------------

Thirty guinea pigs were randomly divided into five groups (six males per group) and an area 5 cm × 5 cm of the back zone of each animal was shaved for treatment. Continuous back shaving was performed two to three times per week during the rest of study (13 weeks).

The shaved skin of experimental animals was rubbed five times per week with the test material at 100, 1000, and 10000 μg/mL and skin of positive controls was rubbed with 100 μg/mL of AgNO~3~ solution; the other parts of body in all treatment groups were kept untreated as negative control. Dermal application was performed once daily for five days per week over a period of 13 weeks.

Clinical examinations
---------------------

Clinical signs were observed and weights were recorded once daily in the acute study and two times per week in the subchronic study. The recording items were divided into three categories: cageside observations, and neurologic and physical examinations.

Pathologic studies
------------------

Tissue was removed from skin, liver, and spleen of three animals per group for histopathologic studies. The tissues were fixed in 10% buffered formalin and dehydrated in a graded series of alcohol, cleared in xylene, and embedded in paraffin wax. Multiple sections from each block were prepared at 5 μm and stained with hematoxylin and eosin (H&E) for histopathologic studies.

Results
=======

TEM studies
-----------

Nanosilver particles were detected in sizes of \<100 nm ([Figure 1](#f1-ijn-6-855){ref-type="fig"}).

XRD examination
---------------

Nanosilver particles were observed in the ranges of 38, 44, 64/5 degrees (2*ϑ*) ([Figure 2](#f2-ijn-6-855){ref-type="fig"}).

Mortality
---------

Because no mortality was recorded during dermal application of different concentrations of nanosilver at doses of up to 10,000 μg/mL in the preliminary study, we considered it to be a nontoxic agent in acute dermal exposure.

Acute dermal toxicity studies
-----------------------------

No abnormal change was detected in the negative control ([Figure 3A](#f3-ijn-6-855){ref-type="fig"}). In the AgNO~3~ group, a reduced thickness of epidermis and increased regular collagen fiber in papillary layer were observed. In addition, mononuclear inflammation was noted in this group of animals ([Figure 3B](#f3-ijn-6-855){ref-type="fig"}).

Although a reduced thickness of epidermis and reduced thickness of papillary layer were seen in the low-dose nanosilver group (100 μg/mL), collagen fibers were regular ([Figure 3C](#f3-ijn-6-855){ref-type="fig"}). Higher levels of histopathologic changes were detected in the high-dose group ([Figure 3D](#f3-ijn-6-855){ref-type="fig"}). It seems that increased concentrations of nanosilver increased the toxic responses of skin. Details of histopathologic abnormalities in the acute study are shown in [Table 1](#t1-ijn-6-855){ref-type="table"}.

Subchronic toxicity test
------------------------

### Skin

Similar skin inflammatory responses were recorded in all treatment groups in the subchronic study. No abnormal change was detected in the negative control ([Figure 4A](#f4-ijn-6-855){ref-type="fig"}). In the AgNO~3~ group, a reduced thickness of the epidermis and papillary layer were seen. Moreover the decreased thickness of dermis and epidermis increased the numbers of Langerhans cells. [Figure 4B](#f4-ijn-6-855){ref-type="fig"} shows inflammation, decreased thickness of the papillary layer, and increased collagen levels of the dermis layer.

In animals treated with 100 μg/mL nanosilver, decreased thickness of epidermis and dermis were detected, as were increased levels of Langerhans cells, inflammation, and decreased papillary layer with regular collagens fibers ([Figure 4C](#f4-ijn-6-855){ref-type="fig"}).

In animals treated with a 1000 μg/mL of nanosilver, a reduced thickness of epidermis and dermis were seen, too. Increased levels of Langerhans cells and round cells, decreased papillary layer with regular collagen fibers and inflammation, and acidophilic cytoplasm in muscle fibers with inflammation were observed in endomysium. In addition some muscle fibers were surrounded by macrophages ([Figure 4D](#f4-ijn-6-855){ref-type="fig"}).

In the animals treated with 10,000 μg/mL nanosilver, muscle fibers with acidophilic cytoplasm were surrounded by macrophages. In addition to degenerative fibers, increased levels of macrophage in endomysium were observed with inflammation. All observed toxic skin responses were dose- and time-dependent, which means that greatest histopathologic changes were seen in the 10,000 μg/mL group in the 13-week study and the lowest in the 100 μg/mL group in the acute test ([Figure 4E](#f4-ijn-6-855){ref-type="fig"}). All details of histopathologic changes in the subchronic test are listed in [Table 2A](#t2A-ijn-6-855){ref-type="table"}.

### Liver

In the AgNO~3~ and nanosilver groups, destruction of hepatocyte cords was seen but in the test groups this pattern was magnified by increased nanosilver concentrations. Moreover, overproduction of Kupffer cells and degeneration of hepatocytes were seen and increased with increasing nanosilver concentrations in the test groups ([Figures 6B--E](#f6-ijn-6-855){ref-type="fig"}). Necrosis was observed only at the highest nanosilver concentration (10,000 μg/mL). Observed histopathologic changes clearly showed necrosis at the maximum nanosilver concentration. Thus, the results suggest a dose-dependent hepatotoxic effect of nanosilver by dermal exposure. More details on histopathologic changes of the liver are listed in [Table 2C](#t2C-ijn-6-855){ref-type="table"}.

### Spleen

Red capsules and white pulp were seen regularly in the spleens of the control group without any abnormal change or inflammation ([Figure 5A](#f5-ijn-6-855){ref-type="fig"}). Red capsules were thinner in the AgNO~3~ group with inflammation and white pulp hypertrophy ([Figure 5B](#f5-ijn-6-855){ref-type="fig"}). In the low-dose (100 μg/mL) group, red capsules were much thinner, with signs of inflammation, accumulation of red blood cells, and white pulp atrophy ([Figure 5C](#f5-ijn-6-855){ref-type="fig"}). In the medium-dose (1000 μg/mL) group the same pattern was repeated ([Figure 5D](#f5-ijn-6-855){ref-type="fig"}). The highest levels of red pulp inflammation, white pulp atrophy, and thinnest capsules were seen in the high-dose group, but white pulp hypertrophy was a specific response to AgNO~3~, not to any nanosilver dose ([Figure 5B](#f5-ijn-6-855){ref-type="fig"}). More details on histopathologic changes of the spleens are shown in [Table 2C](#t2C-ijn-6-855){ref-type="table"}.

Discussion
==========

Nanosilver has become one of the most widely used nanomaterials in consumer products because of its antimicrobial and antiseptic properties. Because of public concern over the potential adverse effects of nanosilver,[@b16-ijn-6-855] we assessed the toxicity potentials of different concentrations of nanosilver by dermal application because our knowledge of toxicology has been derived only from studies on administration of nanosilver inhalational[@b1-ijn-6-855] or by mouth.[@b17-ijn-6-855] In these previous studies, animals exposed to nanosilver showed minimal pulmonary inflammation or cytotoxicity following subacute exposures but longer-term exposures with higher body burdens of nanosilver are needed to ensure that there are no chronic effects and to evaluate possible translocation of nanosilver to other organs.

The present study clearly showed that dermal contact with nanosilver may cause histopathologic abnormalities of the skin, liver, and spleen of animals, which could be magnified by increased concentrations over longer-term exposures. The present study has emphasized also that sub-chronically treated animals exhibit higher dermal, hepatic, and immunological toxicity signs compared with acutely treated animals.

One of the classical toxic responses to the silver is argyria, which was reported for the first time by Blumberg and Carey in a woman who had ingested a total dose of 6.4 g silver nitrate over a 1-year period of time and showed argyria symptoms after the first six months of exposure.[@b18-ijn-6-855] Rosenman et al reported also respiratory irritation, abdominal pain, and decreased night vision in workers exposed to AgNO~3~ and silver oxide dusts over one to ten years.[@b4-ijn-6-855] They later showed that occupational exposure to silver compounds in a group of workers may cause respiratory irritation, decreased night vision, abnormal rise in N-acetyl-B-D glucoseaminidase, and decreased creatinine clearance.[@b19-ijn-6-855] Discoloration of the conjunctiva and cornea in some workers was reported after inhalational exposure.[@b20-ijn-6-855] Williams et al, in a case study of a 51-year-old man exposed to silver compounds, showed corneal and conjunctival argyrosis.[@b21-ijn-6-855] Chang et al recorded a case study of a 59-year-old man who was distressed from dermal and face color change. He had ingested colloidal silver two to three times per year for two years and showed endocrine disruptions such as hyperlipidemia, hypertension, and diabetes as well as blue-grey facial signs.[@b22-ijn-6-855] Neurologic symptoms are an unusual consequence of silver toxicity which was recently reported in a 75-year-old man who had a history of self-medication with colloidal silver and presented with myoclonic seizures.[@b23-ijn-6-855]

Our study clearly showed that the toxic effects of nanosilver depend on the route of administration. Moreover dose- and time-dependent toxic effects of nanosilver via dermal application in skin, liver, and spleen of male guina pigs were completely different from what has been seen after clinical poisoning with silver salts via inhalational or oral routes of administration.

Some reports have proved that many medical devices loaded with silver could release silver ions (Ag^+^) which could be translocated through the blood circulation and accumulate in some organs such as the liver and kidney. It may induce hepatotoxicity or renal toxicity and may lead to death in some cases of extreme exposure to a certain dose of Ag^+^.[@b24-ijn-6-855] We have shown that silver nanoparticles with properties similar to those of Ag^+^ could be translocated in the body and cause histopathologic changes in the liver and spleen unlike those caused by AgNO~3~ given by the same route of administration. For example, mononuclear inflammation was noted for AgNO~3~-treated animals only, whereas reduced epidermal thickness and thickness of papillary layer were seen after administration of different concentrations of nanosilver in our acute study.

Braydich-Stoll et al[@b25-ijn-6-855] reported potential cytotoxicity of nanosilver in vitro. They used nanosilver in different concentrations on mammalian stem cells and showed apoptosis and necrosis in cells exposed to ≥10 μg/mL nanosilver. Mitochondrial function and cell viability were reduced by silver nanoparticles at concentrations of 1 to 5 μg/mL.[@b25-ijn-6-855] We used doses of 10,000, 1000, and 100 μg/mL solutions without recording any sign of mortality. Although the concentrations of nanosilver were high and unrealistic, to our knowledge this is the first study on dermal and systemic toxicity of nanosilver in acute and subchronic treatment. It is necessary to conduct the same study with lower doses and find the NOAEL (no observable adverse effect level) of nanosilver by dermal application.

Conclusion
==========

The target organs for silver nanoparticles were found to be the skin, liver, and spleen in the male guinea pig after dermal application. Although a NOAEL of 30 mg/kg and LOAEL (lowest observable adverse effect level) of 125 mg/kg[@b17-ijn-6-855] were suggested for oral administration of silver nanoparticles in the rat, at doses of 0.1 mg/kg (100 μg) was not a safe dose for dermal application. Although no sign of mortality was detected in any of the treatment groups, significant dose-dependent histopathologic changes were found in all treatment groups compared with controls. The present results indicate that exposure to \>0.1 mg/kg of silver nanoparticles may result in slight liver, spleen, and skin damage. It could be concluded from this study that the toxicity profile of nanosilver differs from that of silver even when given by the same route of administration. The results suggest that it is necessary to determine the association between the period of exposure and histopathologic changes with lower doses over different time periods. The effect of particle shape and size on the toxicity profile of nanosilver administered by different routes should be determined in future studies.
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![TEM image showing nanosilver particles of sizes \<100 nm.](ijn-6-855f1){#f1-ijn-6-855}

![Nanosilver particles by XRD were observed in the ranges of 38, 44, 64/5 degrees (2*θ*).](ijn-6-855f2){#f2-ijn-6-855}

![H&E stained skin sections in an acute toxicity study (× 40). **A**) Negative control; **B**) AgNO~3~ group: reduced thickness of epidermis and increased regular collagen fiber in papillary layer and mononuclear inflammation; **C**) Low-dose nanosilver group with reduced thickness of epidermis, reduced thickness of papillary layer, and regular collagen fibers; **D**) High-dose nanosilver group with reduced thickness of epidermis, reduced thickness of papillary layer, and irregular collagen fibers.](ijn-6-855f3){#f3-ijn-6-855}

![H&E stained skin sections in subchronic toxicity (× 40). **A**) Normal skin in control group; **B**) AgNO~3~ group with reduced thickness of dermis and epidermis, increased Langerhans cells, inflammation, decreased thickness of papillary zone layer, and increased collagen levels of dermis layer; **C**) Skin abnormalities in low-dose nanosilver group; **D**) Skin abnormalities in high-dose nanosilver group; **E**) Highest level of dermal toxicity (see text for further details).](ijn-6-855f4){#f4-ijn-6-855}

![H&E stained liver sections in subchronic toxicity (× 40). **A**) Normal liver in control group; **B**) AgNO~3~ group with hepatic cord deformation; **C**) Overproduction of Kupffer cells and degeneration of hepatocytes in low-dose nanosilver group; **D**) Overproduction of Kupffer cells and degeneration of hepatocyte in medium-dose nanosilver group; **E**) Liver necrosis in nanosilver high-dose group.](ijn-6-855f5){#f5-ijn-6-855}

![H&E stained spleen sections in subchronic toxicity study (× 40). **A**) Normal spleen in control group. **B**) Thin red capsule with inflammation and white pulp hypertrophy in AgNO~3~ group; **C**) Thin capsules with inflammation, accumulation of red blood cells (RBC), and white pulp atrophy in low-dose nanosilver group; **D**) Thin capsules with inflammation, accumulation of RBC, and white pulp atrophy in medium-dose nanosilver group; **E**) The highest levels of red pulp inflammation, white pulp atrophy, and thinnest capsule in high-dose nanosilver group.](ijn-6-855f6){#f6-ijn-6-855}

###### 

Dermal histopathologic changes in acute study

  **Group**                 **Inflammation**   **Round cell**   **Clear cell**   **Reduced epidermis**   **Reduced papillary**
  ------------------------- ------------------ ---------------- ---------------- ----------------------- -----------------------
  Control                   −                  −                −                −                       −
  AgNO~3~                   +\*                \+               −                \+                      −
  Nanosilver 100 μg/mL      \+                 \+               \+               \+                      \+
  Nanosilver 10,000 μg/mL   \+                 ++\*\*           ++               ++                      ++

###### 

Dermal histopathologic changes in subchronic test

  **Group**                 **Inflammation**   **Round cell**   **Clear cell**   **Decreased epidermis**   **Decreases collagen fiber**   **Decreased lamina propria attachments**
  ------------------------- ------------------ ---------------- ---------------- ------------------------- ------------------------------ ------------------------------------------
  Control                   −                  −                −                −                         −                              −
  AgNO~3~                   \+                 −                \+               \+                        \+                             −
  Nanosilver 100 μg/mL      \+                 −                \+               \+                        \+                             −
  Nanosilver 1000 μg/mL     \+                 \+               \+               \+                        ++                             −
  Nanosilver 10,000 μg/mL   \+                 ++               ++               ++                        +++                            ++

**Notes:** Severe (+++); moderate (++); mild (+); none (−).

###### 

Liver histopathologic changes in subchronic test

  **Group**                 **Inflammation**   **Thin capsule**   **White pulp atrophy**   **Red pulp inflammation**   **White pulp hypertrophy**
  ------------------------- ------------------ ------------------ ------------------------ --------------------------- ----------------------------
  Control                   −                  −                  −                        −                           −
  AgNO~3~                   \+                 \+                 −                        \+                          \+
  Nanosilver 100 μg/mL      \+                 \+                 \+                       \+                          −
  Nanosilver 1000 μg/mL     \+                 \+                 \+                       \+                          −
  Nanosilver 10,000 μg/mL   \+                 ++                 ++                       ++                          −

**Notes:** severe (+++); Moderate (++); mild (+); none (−).

###### 

Histopathologic changes of the spleen in subchronic test

  **Group**                 **Inflammation**   **Kupffer cell**   **Limited pale destruction**   **Hepatic cord destruction**   **Necrosis**   **Hepatocyte degeneration**
  ------------------------- ------------------ ------------------ ------------------------------ ------------------------------ -------------- -----------------------------
  Control                   −                  −                  −                              −                              −              −
  AgNO~3~                   \+                 ++                 ++                             ++                             −              ++
  Nanosilver 100 μg/mL      \+                 \+                 \+                             \+                             −              \+
  Nanosilver 1000 μg/mL     ++                 ++                 ++                             ++                             −              ++
  Nanosilver 10,000 μg/mL   ++                 +++                +++                            +++                            \+             +++

**Notes:** Severe (+++); moderate (++); mild (+); none (−).
